ASH 2020 | ZUMA-1: 3-year follow-up on axi-cel in LBCL patients
Frederick Locke, MD, Moffitt Cancer Center, Tampa, FL, shares the findings of long-term follow-up results from the ZUMA-1 Phase I/II trial (NCT02348216) of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL). Axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is approved for use in relapsed/refractory LBCL and has shown high durable response rates in the previously reported 2-year analysis of ZUMA-1. This extended analysis, with a median follow up of 39 months, is concordant with the 2-year findings of durable responses, with a median overall survival (OS) of 25.8 months. When flow cytometry was used to characterize patient B-cells, nearly all patients with ongoing responses at 3-years showed recovery of polyclonal B-cells. It was also observed that over half the ongoing responders had minimal levels of CAR T-cells and a normalized B-cell compartment, suggesting CAR T-cell persistence is not required for extended remission. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
